Currently out of the existing stock ratings of Kennen Mackay, 129 are a BUY (66.15%), 65 are a HOLD (33.33%), 1 are a SELL (0.51%).

Kennen Mackay

Work Performance Price Targets & Ratings Chart

Analyst Kennen Mackay, currently employed carries an average stock price target met ratio of 57.1% that have a potential upside of 22.8% achieved within 217 days. Previously, Kennen Mackay worked at RBC.

Kennen Mackay’s has documented 378 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VIRX, Viracta Therapeutics at 10-Nov-2023.

Wall Street Analyst Kennen Mackay

Analyst best performing recommendations are on XLRN (ACCELERON PHARMA).
The best stock recommendation documented was for SGEN (SEAGEN) at 2/1/2021. The price target of $186 was fulfilled within 4 days with a profit of $23.14 (14.21%) receiving and performance score of 35.52.

Average potential price target upside

of $64.09 (14.3%) on REGN (REGENERON PHARMACEUTICALS).
of $31.03 (25.11%) on ALXN (ALEXION PHARMACEUTICALS).
of $23.82 (52.08%) on ARNA (ARENA PHARMACEUTICALS).

ABEO Abeona Therapeutics AGIO Agios Pharm AIMT Aimmune Therapeutics AKBA Akebia Ther ALXN Alexion Pharmaceuticals AMGN Amgen ANAB AnaptysBio ARNA Arena Pharmaceuticals ATNX Athenex BMRN Biomarin Pharmaceutical CLVS Clovis Oncology EXEL Exelixis FPRX Five Prime Therapeutics GMAB Genmab AS IMGN ImmunoGen OBSV ObsEva SA ONCE Spark Therapeutics PBYI Puma Biotechnology PRTA Prothena plc REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma ADCT ADC Therapeutics SA NUVB Nuvation Bio LIFE aTyr Pharma VIRX Viracta Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)